Displaying 1 - 1 of 1
| Active Ingredient | IPRATROPIUM | SALBUTAMOL |
| Therapeutic Class | RESPIRATORY AGENTS MISCELLANEOUS |
| Indications |
Treating moderate-to-severe COPD; it is indicated primarily in patients who fail to resp ond on ipratropium alone. The role of the combination in acute asthma is unclear. |
| Caution | Tachycardia, dry mouth, Bronchitis, upper respiratory tract infections and headache. |
| Dose Range |
Two inhalations four times daily is indicated in chronic obstructive pulmonary disease. In severe acute asthma, ipratropium 0.5mg/salbutamol 2.5mg via nebulizer has been administered. See BDS supply protocols pg. 10. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |